Image Place holder

Travis Gerke, ScD

Academic Rank: Assistant Member

Overview


Discipline

    • Cancer Epidemiology
    • Genitourinary Oncology
    • Cancer Epidemiology Program

Education & Training

Fellowship:

  • Harvard University, AM - Biostatistics
  • Harvard School of Public Health, Sc.D. -
Research

My active line of research lies in integrative molecular prostate cancer epidemiology, and is driven by concurrent interests in biostatistical methods development and computational biology. Several of my recent publications investigate tumor-based biomarkers that can distinguish aggressive from non-aggressive prostate cancers in large prospective cohorts. My methodological interests in this area concern ways in which high-dimensional data analysis techniques can be modified to discover markers that are highly specific for indolent cancer types. With regard to computational biology and statistics, I also collaborate on efforts to streamline processing, analysis, and epidemiologic translation of large-scale genomic databases such as The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus. Finally, an emerging research interest of mine applies contemporary methods in causal inference to existing clinical trial data in order to discover optimal treatment sequences for metastatic castration-resistant prostate cancer.

Publications

  • Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study. Cancer Med. 2019 Oct.8(17):7399-7407. Pubmedid: 31595713.
  • Gerke T, Awasthi S, Yamoah K. Biology vs Access to Care-Relative Contribution to Racial Disparities in Prostate Cancer. JAMA Oncol. 2019 Oct. Pubmedid: 31670755.
  • Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. Clin Cancer Res. 2019 Nov. Pubmedid: 31754047.
  • Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, Yamoah K, Gerke TA. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk. Cancer Epidemiol Biomarkers Prev. 2019 Nov. Pubmedid: 31757784.
  • Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer P D. 2019 May.22(2):292-302. Pubmedid: 30367117. Pmcid: PMC6760558.
  • Creed JH, Aden-Buie G, Monteiro AN, Gerke TA. epiTAD: a web application for visualizing chromosome conformation capture data in the context of genetic epidemiology. Bioinformatics. 2019 May.35(21):4462-4464. Pubmedid: 31099399.
  • Preston MA, Gerke T, Carlsson SV, Signorello L, Sjoberg DD, Markt SC, Kibel AS, Trinh QD, Steinwandel M, Blot W, Vickers AJ, Lilja H, Mucci LA, Wilson KM. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol. 2019 Mar;75(3):399-407. Pubmedid: 30237027. Pmcid: PMC6390280.
  • Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K. Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study. Cancer Epidemiol Biomarkers Prev. 2019 Mar.28(3):570-577. Pubmedid: 30413401.
  • Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Mar.28(3):584-590. Pubmedid: 30420441. Pmcid: PMC6494092.
  • Fankhauser CD, Gerke TA, Roth L, Sander S, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Beyer J, Hermanns T. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment. J Cancer Res Clin Oncol. 2019 Mar;145(3):781-785. Pubmedid: 30637464.
  • Khan NA, Stopsack KH, Allott EH, Gerke T, Giovannucci EL, Mucci LA, Kantoff PW. Intratumoral Sterol-27-Hydroxylase () Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Jun.28(6):1052-1058. Pubmedid: 30867220. Pmcid: PMC6548616.
  • Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019 Jun.116(23):11390-11395. Pubmedid: 31085648. Pmcid: PMC6561291.
  • Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins S, Nandakumar S, Gerke T, Pomerantz M, Qiu X, Zhao H, Atiq MO, Khan NA, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long H, Freedman M, Kim B, Kantoff PW. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 Jul.25(14):4480-4492. Pubmedid: 30996073. Pmcid: PMC6820162.
  • Creed JH, Peeri NC, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, Gerke TA, Nabors LB, Egan KM. Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma. Sci Rep. 2019 Jul;9(1):10861. Pubmedid: 31350461. Pmcid: PMC6659774.
  • Jones AA, Gerke T, Striley CW, Osborne V, Whitehead N, Cottler LB. A Longitudinal Analysis of the Substance Abuse, Violence, and HIV/AIDS (SAVA) Syndemic among Women in the Criminal Justice System. J Psychoactive Drugs. 2019 Jan.51(1):58-67. Pubmedid: 30626264. Pmcid: PMC6386603.
  • Awasthi S, Gerke T, Williams VL, Asamoah F, Fink AK, Balkrishnan R, Park JY, Yamoah K. Interrelationship Between Health Insurance Status and Prostate Cancer Grade Can Have Critical Impact on Prostate Cancer Disease Control: A Retrospective Cohort Study. Cancer Control. 2019 Jan;26(1). Pubmedid: 30935222. Pmcid: PMC6446254.
  • Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. J Urol. 2019 Aug;202(2):247-255. Pubmedid: 31107158.
  • Stopsack KH, Gerke T, Tyekucheva S, Mazzu YZ, Lee GM, Chakraborty G, Abida W, Mucci LA, Kantoff PW. Low Expression of the Androgen-Induced Tumor Suppressor Gene and Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Apr.28(4):707-714. Pubmedid: 30602500. Pmcid: PMC6532645.
  • Jones AA, O'Leary CC, Striley CW, Gerke T, Crecelius R, Sullivan J, Cottler LB. Substance Use, Victimization, HIV/AIDS Risk, And Recidivism Among Females in A Therapeutic Justice Program. J Subst Use. 2019 Apr.23(4):415-421. Pubmedid: 30930687. Pmcid: PMC6438380.
  • Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, La Rocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Amos CI, Huse JT, Barnholtz-Sloan JS, Bondy ML. Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. Int J Cancer. 2019 Apr.146(3):739-748. Pubmedid: 30963577. Pmcid: PMC6785354.
  • Jones AA, Gerke T, Striley CW, Whitehead N, Osborne V, Cottler LB. One Step at a Time: A Latent Transitional Analysis on Changes in Substance Use, Exposure to Violence, and HIV/AIDS Risk Behaviors among Female Offenders. Am J Crim Justice. 2018 Sep.43(3):471-485. Pubmedid: 30220837. Pmcid: PMC6135105.
  • Wang K, Chen X, Gerke TA, Bird VY, Ghayee HK, Prosperi M. BMI trajectories and risk of overall and grade-specific prostate cancer: An observational cohort study among men seen for prostatic conditions. Cancer Med. 2018 Oct.7(10):5272-5280. Pubmedid: 30207080. Pmcid: PMC6198207.
  • Ren Y, Ay A, Gerke TA, Kahveci T. Identification of jointly correlated gene sets. J Bioinform Comput Biol. 2018 Oct;16(5):1840019. Pubmedid: 30419787.
  • Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Nov.27(11):1376-1383. Pubmedid: 30108099. Pmcid: PMC6214732.
  • Jones AA, Gerke T, Ennis N, Striley CW, Crecelius R, Sullivan JE, Cottler LB. Order in The Court? The Association Between Substance Use, Exposure to Violence, Risky Sexual Behaviors & Observed Court Behaviors Among Women Involved in the Criminal Justice System. J Natl Med Assoc. 2018 Nov.111(2):134-147. Pubmedid: 30409715.
  • Williams VL, Awasthi S, Fink AK, Pow-Sang JM, Park JY, Gerke T, Yamoah K. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015. Cancer Med. 2018 May;7(5):2160-2171. Pubmedid: 29601662. Pmcid: PMC5943433.
  • Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018 Jul;128(7):2979-2995. Pubmedid: 29863497. Pmcid: PMC6025984.
  • Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, Mucci LA, Loda M. MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):201-207. Pubmedid: 29141848. Pmcid: PMC5831163.
  • Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, Fiorentino M, Giovannucci EL, Loda M, Mucci LA. Height, Obesity, and the Risk of -Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):193-200. Pubmedid: 29167279. Pmcid: PMC5809280.
  • Barber LE, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn TU, Giovannucci EL, Parmigiani G, Mucci LA. Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res. 2018 Dec.24(23):5910-5917. Pubmedid: 30082473. Pmcid: PMC6279573.
  • Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou K, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018 Dec;39(12):1431-1437. Pubmedid: 30165429. Pmcid: PMC6314328.
  • Peeri NC, Creed JH, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, Gerke TA, Nabors LB, Egan KM. Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma. Cancer Epidemiol. 2018 Aug;55:45-51. Pubmedid: 29777993.
  • Stopsack KH, Ebot EM, Downer MK, Gerke TA, Rider JR, Kantoff PW, Mucci LA. Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer Causes Control. 2018 Aug;29(8):775-784. Pubmedid: 29915914. Pmcid: PMC6298857.
  • Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer. 2017 Nov;123(21):4130-4138. Pubmedid: 28700821. Pmcid: PMC5802874.
  • Wang K, Chen X, Bird VY, Gerke TA, Manini TM, Prosperi M. Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases. Int J Cancer. 2017 Nov;141(9):1783-1793. Pubmedid: 28699177. Pmcid: PMC6169522.
  • Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, Mucci LA. Perineural Invasion and Risk of Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):719-726. Pubmedid: 28062398. Pmcid: PMC5413395.
  • Pettersson A, Gerke T, Fall K, Pawitan Y, Holmberg L, Giovannucci EL, Kantoff PW, Adami HO, Rider JR, Mucci LA. The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. Cancer. 2017 May;123(9):1490-1496. Pubmedid: 28152172. Pmcid: PMC5716345.
  • Sinnott JA, Peisch S, Tyekucheva S, Gerke TA, Lis RT, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, Penney KL. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res. 2017 Jan;23(1):81-87. Pubmedid: 27663590. Pmcid: PMC5215643.
  • Li D, Mai V, Gerke T, Pinney SM, Yaghjyan L. Interactions of Family History of Breast Cancer with Radiotherapy in Relation to the Risk of Breast Cancer Recurrence. J Breast Cancer. 2017 Dec.20(4):333-339. Pubmedid: 29285037. Pmcid: PMC5743992.
  • Stopsack KH, Gerke TA, Andrén O, Andersson SO, Giovannucci EL, Mucci LA, Rider JR. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis. 2017 Aug;38(8):806-811. Pubmedid: 28595267. Pmcid: PMC6074871.
  • Fankhauser CD, Mucci LA, Gerke TA. Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12. Eur Urol. 2017 07;72(1):e9-e10. Pubmedid: 28108146.
  • Mucci LA, Pernar CH, Peisch S, Gerke T, Wilson KM. Prostate cancer incidence as an iceberg. Eur J Epidemiol. 2017 06;32(6):477-479. Pubmedid: 28560536. Pmcid: PMC5709244.
  • Waniga HM, Gerke T, Shoemaker A, Bourgoine D, Eamranond P. The Impact of Revised Discharge Instructions on Patient Satisfaction. J Patient Exp. 2016 Sep.3(3):64-68. Pubmedid: 28725840. Pmcid: PMC5513645.
  • Conboy L, Gerke T, Hsu KY, St John M, Goldstein M, Schnyer R. The Effectiveness of Individualized Acupuncture Protocols in the Treatment of Gulf War Illness: A Pragmatic Randomized Clinical Trial. PLoS One. 2016 Mar;11(3):e0149161. Pubmedid: 27031099. Pmcid: PMC4816551.
  • Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res. 2016 Feb;22(3):765-772. Pubmedid: 26490316. Pmcid: PMC4738177.
  • Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb;108(2). Pubmedid: 26615022. Pmcid: PMC4862436.
  • Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016 Dec.4:22. Pubmedid: 27980733. Pmcid: PMC5142400.
  • Preston MA, Batista JL, Wilson KM, Carlsson SV, Gerke T, Sjoberg DD, Dahl DM, Sesso HD, Feldman AS, Gann PH, Kibel AS, Vickers AJ, Mucci LA. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol. 2016 Aug;34(23):2705-2711. Pubmedid: 27298404. Pmcid: PMC5019757.
  • Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR. Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res. 2016 Aug;76(16):4785-4790. Pubmedid: 27325648. Pmcid: PMC4987257.
  • Terry RS, Gerke T, Mason JB, Sorensen MD, Joseph JP, Dahm P, Su LM. Postoperative rhabdomyolysis following robotic renal and adrenal surgery: a cautionary tale of compounding risk factors. J Robot Surg. 2015 Sep;9(3):195-200. Pubmedid: 26531199.
  • Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, Loda M. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Oct;13(10):1431-1440. Pubmedid: 26124442. Pmcid: PMC4618038.
  • Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, Gerke T, Albanes D, Mucci LA, Giovannucci E, Kraft P. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015 Jun;121(12):1949-1956. Pubmedid: 25731953. Pmcid: PMC4457645.
  • Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson SO, Andrén O. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun;36(6):632-638. Pubmedid: 25870172. Pmcid: PMC4572920.
  • Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S. Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015 Jun;36(6):639-647. Pubmedid: 25863129. Pmcid: PMC4481603.
  • Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, Mucci LA, Stampfer MJ. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):255-260. Pubmedid: 25371445. Pmcid: PMC4294966.
  • Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, Mucci LA. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate. 2015 Dec;75(16):1926-1933. Pubmedid: 26469352. Pmcid: PMC4831584.
  • Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Le Marchand L, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun;65(6):1069-1075. Pubmedid: 24411283. Pmcid: PMC4006298.
  • Bismar TA, Alshalalfa M, Petersen LF, Teng LH, Gerke T, Bakkar A, Al-Mami A, Liu S, Dolph M, Mucci LA, Alhajj R. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. BJU Int. 2014 Feb;113(2):309-319. Pubmedid: 24006850.